Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400511 | 0.93 | ACE2 (0.46) | ACE2SLC2A1PAOXGNAI3GNAO1 | |
| SCHEMBL13822725 | 0.91 | ACE2 (0.48) | ACE2SLC2A1PAOXUSP2GNAI3 | |
| SCHEMBL4396749 | 0.91 | ACE2 (0.48) | ACE2SLC2A1PAOXUSP2GNAI3 | |
| SCHEMBL18121254 | 0.91 | ACE2 (0.48) | ACE2SLC2A1PAOXUSP2GNAI3 | |
| SCHEMBL5672803 | 0.87 | ACE2 (0.59) | ACE2PAOXTP53SMN1; SMN2 | |
| SCHEMBL2443844 | 0.86 | ALDH1A1 (0.56) | ACE2SLC2A1PAOXUSP2GNAI3 | |
| SCHEMBL4396790 | 0.86 | ACE2 (0.48) | ACE2SLC2A1PAOXUSP2ALDH1A1 | |
| SCHEMBL4401317 | 0.85 | ACE2 (0.58) | ACE2SLC2A1SMN1; SMN2DRD2SIGMAR1 | |
| SCHEMBL8875471 | 0.85 | ACE2 (0.56) | ACE2PAOXTP53SMN1; SMN2 | |
| SCHEMBL8876012 | 0.85 | ACE2 (0.56) | ACE2PAOXTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | MITSUI CHEMICALS, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20070054084-A1 | Optical recording medium and compound used for the same | MITSUI CHEMICALS, INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1672626-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM | Mitsui Chemicals, Inc. (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | CACNA1B, KCNN4, KCNN2 | ACE2 2695/4885SLC2A1 3034/4885PAOX 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.